At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GLSI Greenwich Lifesciences Inc
Trading 08-20 11:21:35 EDT
16.19
-1.15
-6.63%
High17.68Low16.10Vol36.11K
Open17.35D1 Closing17.34Amplitude9.11%
Mkt Cap237.64MTradable Cap123.90MTotal Shares14.68M
T/O607.01KT/O Rate0.47%Tradable Shares7.65M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Greenwich Lifesciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-13
Greenwich Lifesciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Greenwich Lifesciences Inc Expected to Post a Loss of 33 Cents a Share - Earnings Preview
Reuters  ·  08-11
Greenwich Lifesciences Inc Expected to Post a Loss of 33 Cents a Share - Earnings Preview
Greenwich LifeSciences extends lock-up of directors and officers to 2027
TIPRANKS  ·  08-10
Greenwich LifeSciences extends lock-up of directors and officers to 2027
Greenwich Lifesciences - Extends Lock-up of Directors, Officers, Pre-IPO Investors' Shares to January 31, 2027
THOMSON REUTERS  ·  08-10
Greenwich Lifesciences - Extends Lock-up of Directors, Officers, Pre-IPO Investors' Shares to January 31, 2027
Greenwich LifeSciences Extends Insider Lock-up to Jan. 31, 2027
Reuters  ·  08-10
Greenwich LifeSciences Extends Insider Lock-up to Jan. 31, 2027
Top Executive Doubles Down on Greenwich LifeSciences With Fresh Insider Buy
TIPRANKS  ·  07-31
Top Executive Doubles Down on Greenwich LifeSciences With Fresh Insider Buy
Top Executive Makes Bold Insider Move on Biotech Stock
TIPRANKS  ·  07-30
Top Executive Makes Bold Insider Move on Biotech Stock
Greenwich Lifesciences CEO and CFO Snehal Patel Acquires $20,430 of Common Shares
Reuters  ·  07-29
Greenwich Lifesciences CEO and CFO Snehal Patel Acquires $20,430 of Common Shares
Top Executive Makes Bold Insider Move at Greenwich LifeSciences
TIPRANKS  ·  07-28
Top Executive Makes Bold Insider Move at Greenwich LifeSciences
Greenwich LifeSciences CEO, CFO Snehal Patel Acquires Common Shares Worth $47,005
Reuters  ·  07-27
Greenwich LifeSciences CEO, CFO Snehal Patel Acquires Common Shares Worth $47,005
Greenwich Lifesciences Announces Approval to Expand Flamingo-01 into the United Kingdom
THOMSON REUTERS  ·  07-22
Greenwich Lifesciences Announces Approval to Expand Flamingo-01 into the United Kingdom
Greenwich Lifesciences Wins UK Regulatory Clearance to Expand Flamingo-01 Trial
Reuters  ·  07-22
Greenwich Lifesciences Wins UK Regulatory Clearance to Expand Flamingo-01 Trial
Greenwich Lifesciences is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  07-22
Greenwich Lifesciences is Maintained at Buy by HC Wainwright & Co.
Greenwich Lifesciences, Inc. : H.c. Wainwright Raises Target Price to $69 from $50
THOMSON REUTERS  ·  07-22
Greenwich Lifesciences, Inc. : H.c. Wainwright Raises Target Price to $69 from $50
Greenwich Lifesciences Rises as Regulators Allow Expansion of Late-stage Breast Cancer Study
Reuters  ·  07-20
Greenwich Lifesciences Rises as Regulators Allow Expansion of Late-stage Breast Cancer Study
Greenwich LifeSciences provides clinical and financial updates on Flamingo-01
TIPRANKS  ·  07-20
Greenwich LifeSciences provides clinical and financial updates on Flamingo-01
Greenwich Lifesciences - Flamingo-01 Phase 3 Objectives Met Following FDA and Ema Review
THOMSON REUTERS  ·  07-20
Greenwich Lifesciences - Flamingo-01 Phase 3 Objectives Met Following FDA and Ema Review
Greenwich Lifesciences Provides Clinical Updates on Flamingo-01
THOMSON REUTERS  ·  07-20
Greenwich Lifesciences Provides Clinical Updates on Flamingo-01
Greenwich Lifesciences - Q2 2026 Burn Rate Expected at $2 Mln; Cash Balance $8.90 Mln as of June 30, 2026
THOMSON REUTERS  ·  07-20
Greenwich Lifesciences - Q2 2026 Burn Rate Expected at $2 Mln; Cash Balance $8.90 Mln as of June 30, 2026
Greenwich Lifesciences - Flamingo-01 Steering Committee Endorses Study Size Increase and Accelerated Enrollment
THOMSON REUTERS  ·  07-20
Greenwich Lifesciences - Flamingo-01 Steering Committee Endorses Study Size Increase and Accelerated Enrollment
No data available

Introduction

Company Name.
Greenwich Lifesciences Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Issue price:
--